Adiponectin hinders migration and invasion by reversing epithelial-mesenchymal transition in NSCLC carcinoma, presenting its promise as a therapeutic strategy for addressing NSCLC [188]. Here, ADIPOQ is linked to non-small cell lung carcinoma.